American Cáncer Society Recommends PSA Screening Every Two Years for Men 50-69

Men aged 50 to 69 in the United States should now have a PSA blood test every two years to screen for prostate cancer, the American Cancer Society said on Thursday — a reversal of more than a decade of guidance that left the decision to each patient and doctor, according to Diario El Día de La Plata.

The updated guidelines, published in the ACS journal CA: A Cancer Journal for Clinicians, also tell Black men and those with a strong family history of prostate cancer to start annual screening at 45. Prostate cancer is the second leading cause of cancer death among American men, and the ACS projects roughly 333,830 new diagnoses and 36,320 deaths in 2026.

“This is a real shift from previous recommendations,” said Philipp Dahm, a professor of urology at the University of Minnesota, who was not involved in writing the guidelines.

American Cáncer Society Recommends PSA Screening Every Two Years for Men 50-69
Photo: Diario El Día de La Plata

Since 2010, the ACS had advised men at average risk to discuss PSA testing with their doctors rather than recommend it outright. The US Preventive Services Task Force, a government advisory panel, still holds that shared-decision position for men aged 55 to 69. In 2023, fewer than 40 percent of men in that age group received a PSA test.

In Plain English: What the New PSA Schedule Means

  • If you are 50 to 69 with average risk, the ACS now advises a PSA blood test every two years — not just a conversation about whether to test.
  • If you are Black, or have a father, brother or son diagnosed with prostate cancer before 65 (or several close relatives affected at any age), start at 45 and test yearly.
  • A high PSA does not mean cancer. The guideline says to repeat the test first, then get an MRI before any biopsy.

Why the American Cancer Society Reversed Course

Robert Smith, senior vice president of early cancer detection science at the ACS, pointed to new 23-year follow-up data from a large randomized controlled trial in Europe. Men who underwent regular screening had a 13 percent lower risk of dying from prostate cancer than men who did not — about two deaths avoided per 1,000 men screened.

The European trial also found screening reduced the incidence of metastatic disease, cancer that has spread beyond the prostate. And an ACS analysis published last year suggested that advanced prostate cancer diagnoses rose after a period in which screening was not recommended.

Smith also cited changes in how doctors now handle an elevated PSA: repeated tests, MRI before biopsy, and active surveillance — regular monitoring rather than immediate treatment — for low-risk tumors.

“Given the burden of the disease and the fact that many men still want to undergo regular testing for prostate cancer, we consider it important to make clear that prostate cancer screening saves lives,” he said. “We have strategies that, if applied, will significantly reduce the risk of harms.”

Prostate cancer screening nat
Photo: Spectrum Noticias

“The way most physicians will implement this is that they will simply test everyone. There are still many harms. And I’m not sure it’s going to have the benefits they predict.” — Alex Krist, professor of family medicine at Virginia Commonwealth University, who helped write the 2018 US Preventive Services Task Force guideline, as quoted by La Nación

The Overdiagnosis Problem the New Rules Try to Fix

Overdiagnosis means finding cancers that would never have caused harm during a man’s lifetime; overtreatment means subjecting those cancers to surgery or radiation that can cause erectile dysfunction, urinary incontinence and bowel problems.

The task force estimated that for every 1,000 men offered screening, 100 real cancers would be diagnosed — and up to half of them would never have grown, spread or caused problems. Most would be treated anyway; 65 men would experience erectile dysfunction or urinary incontinence, and five would still die of prostate cancer despite treatment.

Dahm noted the new guidelines build in safeguards: testing every two years instead of annually, and limiting screening to an age group more likely to benefit. The ACS also no longer recommends the digital rectal exam as a primary screening tool. As the outlet Late931 reported, the evidence the guideline cited found a pooled detection rate of roughly 1 percent with the rectal exam versus about 3 percent with PSA.

American Cáncer Society Recommends PSA Screening Every Two Years for Men 50-69
Photo: American Cancer Society Press Room

Why Screening Starts Younger for Black Men

Black men in the United States are about 1.7 times more likely than white men to be diagnosed with prostate cancer and nearly twice as likely to die of it, and diagnoses begin rising at earlier ages. That is why the guideline sets the starting age at 45 for them.

Otis Brawley, a professor of oncology and epidemiology at Johns Hopkins University who studies cancer disparities, told La Nación he understands the earlier start, but said he is not aware of evidence that prostate cancer behaves more aggressively in Black men, according to LA NACION.

The main reason for worse outcomes, he said, is lower access to high-quality care: when Black men receive the same care within the same hospital system as white men, research shows similar outcomes.

Screening by Age and Risk Under the New ACS Guideline

Group When to start How often
Average-risk men, ages 50–69 50 Every two years
Black men; strong family history 45 Yearly
Men 70–74 Individualized decision Discuss with a doctor
Age 75+ Not recommended —
Life expectancy under 10 years Discouraged —

The ACS estimates for 2026 — roughly 333,830 diagnoses and 36,320 deaths — frame the stakes. Prostate cancer accounts for about 2.5 percent of all deaths among American men. The ACS press release states the update aims to prevent advanced-stage diagnoses, reduce premature deaths and minimize treatment-related harms.

What Happens After an Elevated PSA

The guideline lays out a stepwise path. A man with a high PSA should first repeat the blood test, since benign prostate enlargement, recent physical activity and other conditions can raise levels.

If the second result is still abnormal, the ACS recommends an MRI to distinguish low-risk from high-risk tumors, with a biopsy to confirm. Tumors that appear low-risk can be managed with active surveillance — periodic PSA tests, medical follow-up and control biopsies — instead of immediate surgery or radiation.

American Cáncer Society Recommends PSA Screening Every Two Years for Men 50-69
Photo: infobae

Contraindications & When to Consult a Doctor

  • The ACS discourages screening from age 80 onward and for anyone with a life expectancy of less than 10 years.
  • For men 70 to 74, the benefit-risk balance remains uncertain; the guideline calls for an individualized decision with a physician.
  • Men who have had a single first-degree relative diagnosed at 65 or older should screen every two years between 45 and 69, per the ACS press release.
  • Discuss with your doctor before testing if you have a history of benign prostate enlargement or a recent urinary infection, which can elevate PSA without cancer.

The Question Left Open

The guideline still requires a conversation between doctor and patient about benefits and limits, and some experts worry the clearer recommendation will sweep men into testing without that discussion. “We want to find the right balance,” urologist Tewari told Spectrum Noticias.

“Patients need to understand that their prostate cancer risk is different.” Whether the ACS’s safeguards — biennial testing, MRI before biopsy, active surveillance — actually deliver the predicted benefits without the old harms is something the data has not yet answered.

References

  • American Cancer Society, updated prostate cancer screening guideline, CA: A Cancer Journal for Clinicians — acsjournals.onlinelibrary.wiley.com
  • American Cancer Society patient-page version of the guideline — acsjournals.onlinelibrary.wiley.com
  • American Cancer Society press room, guideline update announcement — American Cancer Society Press Room
  • La Nación, reporting on the new guidelines and expert reaction
  • The New York Times en Español, Spectrum Noticias, Diario El Día de La Plata, Late931 and infobae, corroborating coverage

Photo of author

Health Desk

Health Desk at Archyde.

Vincent Kompany Leads First Bayern Munich Training Session Since Hospitalization

Vatican News: Pope Calls Charity an Oasis at Callao Elderly Home